About Enanta
Enanta is a publicly listed company based in Watertown (United States) founded in 1998. Small molecule drugs for infectious and liver diseases are developed. Enanta has raised $21.2 million across 2 funding rounds from investors including Swiss Life, Oxford Bioscience Partners and Advent International. The company has 131 employees. Its chief executive, as recorded, is Jay Luly. Enanta offers products and services including Hepatitis C Virus Treatment, Hepatitis B Virus Treatment, Respiratory Syncytial Virus Program, SARS-CoV-2 Treatment, and Immunology Therapeutics. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its legal entity is Enanta Pharmaceuticals, Inc. Its competitors include Moderna, Adaptive Biotechnologies and Novavax; 2 of its 3 listed competitors have raised funding.
Company details
Enanta was founded in 1998 and is headquartered in Watertown, United States, within the biotechnology sector. Small molecule drugs targeting infectious diseases, including COVID-19, respiratory syncytial virus, hepatitis B virus, and human metapneumovirus, are developed. The lead candidate, EDP-235, serves as an oral coronavirus protease inhibitor. Additional protease inhibitors, glecaprevir and paritaprevir, are advanced for related viral treatments.
- Headquarters Watertown, United States
- Employees 131
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website enanta.com
- Social LinkedIn X
- Legal Name Enanta Pharmaceuticals, Inc.
- Annual Revenue$65.32 M (USD)-3.42as on Sep 30, 2025
- Net Profit-$81.89 M (USD)29.43as on Sep 30, 2025
- EBITDA-$80.76 M (USD)32.33as on Sep 30, 2025
- Total Equity Funding$21.2M (USD)
in 2 rounds
- Latest Funding Round$9.2M (USD), Private Equity Round
Sep 2013
- InvestorsSwiss Life
& 7 more
- Employee Count131
Products & Services of Enanta
Enanta offers a comprehensive portfolio of products and services, including Hepatitis C Virus Treatment, Hepatitis B Virus Treatment, Respiratory Syncytial Virus Program, SARS-CoV-2 Treatment, and Immunology Therapeutics.
Therapeutic for treating chronic hepatitis C infections.
Drug development for managing hepatitis B virus.
Therapeutics targeting respiratory syncytial virus infections.
Solutions for COVID-19 and related viral diseases.
Development of drugs for immunology-related conditions.
Funding Insights of Enanta
Enanta has successfully raised a total of $21.2M across 2 strategic funding rounds. The most recent funding activity was a Private Equity Round of $9.2 million completed in September 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $21.2M
- Total Rounds 2
- Last Round Private Equity Round — $9.2M
- First Round $12M
(Jun 2004)
- Investors Count 8
All 2 funding rounds of Enanta with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2013 | $9.2M | Private Equity Round | – | – | – |
| Jun 2004 | $12M | Private Equity Round | – | – |
8 investors in total: 8 institutional.
Investors in Enanta
Enanta has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Swiss Life, Oxford Bioscience Partners and Advent International.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early stage VC firm investing in the US and Korea | oxbio.com | Boston, United States | ||
Private equity firm focused on multiple sectors | adventinternational.com | Sao Paulo, Brazil | ||
Investment in emerging and growth-stage MedTech companies is facilitated. | bioventuresinvestors.com | Marlborough, United States | ||
| NIB Capital | ||||
Tech-based companies are invested in by Wheatley Partners. | wheatleypartners.com | Great Neck, United States | ||
| yedvc.co.jp | ||||
| tvmvc.com | ||||
Provider of asset management, pensions, financial planning, health insurance, and mortgages | 1857 | swisslife.com | Zurich, Switzerland |
Investor details for Enanta
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Enanta
68 people are tracked at Enanta (23 in leadership, 8 in board & advisors, 37 in team); the tracked headcount is 131.
| Name | Role | Group |
|---|---|---|
Jay Luly | CEO | Leadership |
Yat Sun Or | SVP, Research & Development and Chief Scientific Officer | Leadership |
Kristin Baptista | Director Of Fp&a | Leadership |
Lindsey Theriault | Associate Director, Accounting & Assistant Controller | Leadership |
Scott T. Rottinghaus | SVP & Chief Medical Officer | Leadership |
Paul J. Mellett | SVP, Finance & Administration & Chief Financial Officer | Leadership |
Kristin Kleber-Sanderson | Vice President Clinical Operations | Leadership |
Yao-Ling Qiu | Senior Director Of Medicinal Chemistry | Leadership |
Scott Mitchell | Vice President Of Chemistry | Leadership |
Joseph Helble | Director Analytical Development CMC | Leadership |
Eoin C. | Senior Director Clinical Research | Leadership |
Christopher Harris | Medical Director | Leadership |
Chanthang R. | Associate Director Of Human Resources Operations | Leadership |
Alaa Ahmad | Vice President, Clinical Pharmacology | Leadership |
Rossana C. | Senior Manager, Head Of Compound Management | Leadership |
Mona Carbonneau | Executive Director Human Resources | Leadership |
Robert Mo | Senior Director, CMC Drug Product Development | Leadership |
Manami Shizuka | Executive Director, Research Project Management | Leadership |
Jody Schiloski | Sr Director, Regulatory Affairs | Leadership |
Jeffrey Higgins M.m. | Executive Director Of Facilities And Lab Operations At Enanta Pharmaceuticals | Leadership |
48 more people are available in the full profile.
Complete people profiles for Enanta
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Enanta
Enanta is a publicly listed company on the NASDAQ with ticker symbol ENTA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Mar 2013
- Listed onNASDAQ: ENTA
- Listed entityEnanta Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS29251M1062
- Share price$11.52 (-6.34% on the day) · 2026-10-13
- Market capitalisation$335.5M
- EPS (diluted, trailing year)$-2.41
- Volume (last session)173,991
Financials of Enanta
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $65.3M | -$81.9M | -$80.8M |
| 2024 | $67.6M | -$116.0M | -$119.4M |
| 2023 | $79.2M | -$133.8M | -$134.8M |
| 2022 | $86.2M | -$121.8M | -$120.9M |
| 2021 | $97.1M | -$79.0M | -$106.2M |
Detailed financial statements for Enanta
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Enanta
4 dated milestones of Enanta across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Enanta is founded.
- Funding First funding round of $12.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Private Equity Round, of $9.2M.
Competitors of Enanta
Enanta has 3 listed competitors in our database, 2 of them funded. They include Moderna, Adaptive Biotechnologies and Novavax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| novavax.com | 1987 | Gaithersburg, United States | 184 | Novel vaccines are developed using nanoparticle and matrix adjuvant technology. |
Detailed competitors of Enanta
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Enanta
The website of Enanta (enanta.com) receives about 5.6K visits a month and ranks #4,030,810 among all websites worldwide, #5,063 in Biotechnology and Pharmaceuticals.
- Monthly visits5.6K
▲ 28.6% vs previous month
- Unique visitors1.9K
per month
- Global rank#4,030,810
among all websites
- Category rank#5,063
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit1.8
- Average visit10 sec
- DevicesDesktop 37% · Mobile 63%
Websites whose visitors overlap most with Enanta. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
clinicaltrials.jp | clinicaltrials.jp | 100% | – | ||
novirio.com | novirio.com | 93% | – | ||
 hepatitiscnewdrugs.blogspot.com | hepatitiscnewdrugs.blogspot.com | 59% | – | ||
hepcprimer.com | hepcprimer.com | 59% | – | ||
hcvinprison.org | hcvinprison.org | 58% | #13,674,158 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for Enanta
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Enanta (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Enanta
Complete news archive for Enanta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enanta
Enanta was founded in 1998 and raised its 1st funding round 6 years after it was founded.
Enanta is headquartered in Watertown, United States.
Jay Luly is the CEO of Enanta, as recorded in our data.
Enanta is a funded company, having raised a total of $21.2M across 2 funding rounds to date. The company's 1st funding round was a Private Equity Round of $12M, raised on Jun 2004.
Enanta has 131 employees.
Annual revenue of Enanta is $65.32M as on Sep 30, 2025.
Enanta was founded in 1998 and is headquartered in Watertown, United States, within the biotechnology sector. Small molecule drugs targeting infectious diseases, including COVID-19, respiratory syncytial virus, hepatitis B virus, and human metapneumovirus, are developed. The lead candidate, EDP-235, serves as an oral coronavirus protease inhibitor. Additional protease inhibitors, glecaprevir and paritaprevir, are advanced for related viral treatments.
Enanta's top competitors include Moderna, Adaptive Biotechnologies and Novavax.
Enanta offers Hepatitis C Virus Treatment, Hepatitis B Virus Treatment, Respiratory Syncytial Virus Program, SARS-CoV-2 Treatment, and Immunology Therapeutics.
Yes, Enanta is publicly traded on NASDAQ under the ticker symbol ENTA.
Enanta has 8 investors. Key investors include Swiss Life, Oxford Bioscience Partners, Advent International, BioVentures MedTech Funds, and NIBC Bank.
Enanta operates through Enanta Pharmaceuticals, Inc..